Is CHRS or CRDF more undervalued in 2026?

CirclFi compares Coherus Oncology, Inc. (CHRS) and Cardiff Oncology, Inc. (CRDF) using 13 institutional-grade valuation models. CHRS has a Quality of Company score of 6.8/10 while CRDF scores 5.9/10.

Which is a better buy — CHRS or CRDF?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CHRS and CRDF valuations compare?

CHRS at $1.59 and CRDF at $1.90 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CHRS vs CRDF Valuation Comparison 2026 — Intrinsic Value Analysis

CHRS

Biological Products, (No Diagnostic Substances)

Coherus Oncology, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$1.59

Last close

Models

10/13

Active

CRDF

Biological Products, (No Diagnostic Substances)

Cardiff Oncology, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$1.90

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CHRS Fair Value	CHRS Upside	CRDF Fair Value	CRDF Upside
Bayesian DCF	Intrinsic	$0.53	-66.6%	$0.57	-70.2%
Earnings Power Value	Intrinsic	$9.90	+450.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.47	-73.6%	$0.06	-96.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CHRS vs CRDF — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CHRS vs CRDF — Which Stock Is More Undervalued?

CHRS scores higher with a 6.8/10 quality rating vs CRDF's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Coherus Oncology, Inc. (CHRS) and Cardiff Oncology, Inc. (CRDF) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CHRS currently trades at $1.59 with a QOC of 6.8/10, while CRDF trades at $1.90 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).